NCT01272128 (AVAIL) is a clinical trial of Interferon beta-1a in Multiple Sclerosis, sponsored by Biogen.

Who is sponsoring NCT01272128?

NCT01272128 is sponsored by Biogen.

What drugs are being tested in NCT01272128?

Interventions in NCT01272128: Interferon beta-1a.

What condition does NCT01272128 study?

NCT01272128 studies Multiple Sclerosis.

Is NCT01272128 still recruiting?

NCT01272128 is currently completed. Last updated 16 October 2015.

Last reviewed 2015-10-16 · How we verify

NCT01272128: AVAIL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Prospective Non-interventional Study to Evaluate the Quality of Life in Belgian Patients With CIS or RRMS in Whom Interferon Beta-1a IM Treatment Has Been Initiated

Completed Last updated 16 October 2015

What this trial tests

trial testing Interferon beta-1a in Multiple Sclerosis in 100 participants. Completed in 1 September 2015.

Timeline

1 December 2012

Primary endpoint
1 September 2014

1 September 2015

Quick facts

Lead sponsor	Biogen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 December 2012
Primary completion	1 September 2014
Estimated completion	1 September 2015
Sites	17 locations across Belgium

Drugs / interventions tested

Interferon beta-1a (INTERFERON BETA-1A) — full drug profile →

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Biogen — full company profile →

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from Baseline in EuroQol 5D (EQ-5D) Visual Analog Scale (VAS) at 12 months
Time frame: Baseline and Month 12
Quality of life will be assessed on a visual analog scale from 0 = worst imaginable health status to 100 = best imaginable health status.

Sponsor's own description

The primary objective is to assess the quality of life of intramuscular (IM) Interferon Beta-1a in participants with relapsing remitting multiple sclerosis (RRMS) or Clinically Isolated Syndrome (CIS) in a clinical practice setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Interferon beta-1a

Trials testing the same drug.

NCT06019130 — Nivolumab in Children and Adults With Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT05298670 — Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients · Phase 2 · unknown
NCT04647669 — World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments · Phase 3 · unknown
NCT04492475 — Adaptive COVID-19 Treatment Trial 3 (ACTT-3) · Phase 3 · completed
NCT05024006 — Public Health Emergency: SOLIDARITY TRIAL Philippines · NA · completed

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other Biogen trials

Trials by the same sponsor.

NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
NCT07444450 — A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy · Phase 3 · not yet recruiting
NCT07444489 — A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants · Phase 3 · not yet recruiting
NCT07444476 — A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years Wit · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01272128 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biogen
Last refreshed: 16 October 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01272128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing